Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNi-BiOTiC FLORA plus+ in Bacterial Vaginosis
NCT06888518Phase 1Terminated
- Sponsor
- Institut AllergoSan
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Institut AllergoSan. Primary endpoint: Reduction of patients with Bacterial Vaginosis at 4 weeks. Started Dec 2022; status: terminated.
Beyond the preview
Go deeper on NCT06888518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888518.